TIVOZANIB VEGFR Tyrosine Kinase Inhibitor Angiogenesis Inhibitor Oncolytic

Tivozanib is a novel oral quinoline urea derivative with potent and selective activity against vascular endothelial growth factor (VEGFR) tyrosine kinase. Preclinical data indicate that tivozanib blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo. Tivozanib has been shown to be safe and orally bioavailable when given to cancer patients. Early clinical trials demonstrated inhibition of angiogenesis and tumor progression in several types of advanced solid tumors. The compound is under early clinical investigation for the treatment of renal cell carcinoma and non-small cell lung carcinoma, as well as in combination with other chemotherapies in breast, colorectal, and other gastrointestinal cancer patients.